These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9609635)

  • 1. Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy.
    Bauer JJ; Srivastava S; Connelly RR; Sesterhenn IA; Preston DM; McLeod DG; Moul JW
    Urology; 1998 Jun; 51(6):970-6. PubMed ID: 9609635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
    Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
    J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
    Moul JW
    Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy.
    Bauer JJ; Connelly RR; Sesterhenn IA; Bettencourt MC; McLeod DG; Srivastava S; Moul JW
    Cancer; 1997 Mar; 79(5):952-62. PubMed ID: 9041158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery.
    Stapleton AM; Zbell P; Kattan MW; Yang G; Wheeler TM; Scardino PT; Thompson TC
    Cancer; 1998 Jan; 82(1):168-75. PubMed ID: 9428494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.
    Stackhouse GB; Sesterhenn IA; Bauer JJ; Mostofi FK; Connelly RR; Srivastava SK; Moul JW
    J Urol; 1999 Dec; 162(6):2040-5. PubMed ID: 10569564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathologic characteristics of familial prostate cancer in Asian population.
    Kim M; Kim JK; Ye C; Lee H; Oh JJ; Lee S; Jeong SJ; Lee SE; Hong SK; Byun SS
    Prostate; 2020 Jan; 80(1):57-64. PubMed ID: 31664733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
    Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial prostate cancer: a different disease?
    Kupelian PA; Klein EA; Witte JS; Kupelian VA; Suh JH
    J Urol; 1997 Dec; 158(6):2197-201. PubMed ID: 9366343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
    Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
    Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.
    Bettencourt MC; Bauer JJ; Sesterhenn IA; Connelly RR; Moul JW
    J Urol; 1998 Aug; 160(2):459-65. PubMed ID: 9679898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
    Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
    Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial and hereditary prostate cancer by definition in an italian surgical series: clinical features and outcome.
    Sacco E; Prayer-Galetti T; Pinto F; Ciaccia M; Fracalanza S; Betto G; Pagano F
    Eur Urol; 2005 Jun; 47(6):761-8. PubMed ID: 15925070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression.
    Grossfeld GD; Carroll PR; Lindeman N; Meng M; Groshen S; Feng AC; Hawes D; Cote RJ
    Urology; 2002 Jan; 59(1):97-102. PubMed ID: 11796289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases.
    Azzouzi AR; Valeri A; Cormier L; Fournier G; Mangin P; Cussenot O
    Urology; 2003 Jun; 61(6):1193-7. PubMed ID: 12809896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
    Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.
    Bauer JJ; Connelly RR; Seterhenn IA; Deausen J; Srivastava S; McLeod DG; Moul JW
    J Urol; 1998 Mar; 159(3):929-33. PubMed ID: 9474185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.